|Dr. Ray Prudo||Exec. Chairman||618k||N/A||1945|
|Mr. Clive Richardson||COO, CEO & Director||808.23k||N/A||1965|
|Dr. Torsten Hombeck||Chief Financial Officer||309.86k||N/A||1970|
|Dr. Miles Nunn||Chief Scientific Officer||N/A||N/A||N/A|
|Annie Mack||Financial Controller||N/A||N/A||N/A|
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barrÃ© syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Akari Therapeutics, Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.